Navigation Links
EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million
Date:8/6/2009

    ATHENS, Greece, August 6 /PRNewswire/ --

    - Not for Release, Publication or Distribution Directly or Indirectly in
      or Into the United States, Canada, Australia, South Africa or Japan or
      any Other Jurisdiction in Which Such Publication or Distribution Would
      be Unlawful

    - This Announcement is not a Prospectus and is not an Offer to Sell or a
      Solicitation of any Offer to buy any Securities in the United States or
      in any Other Jurisdiction

Alapis S.A. ("Alapis" or "the Company") announces that, on 5 August, 2009, the Company's Board of Directors approved a share capital increase by way of pre-emptive rights for existing shareholders that will increase the Company's share capital by EUR 294,180,066.

The share capital increase will be effected through the issue of 980,600,220 new ordinary shares of a nominal value EUR0.30 each, with payment in cash.

Shareholders of Alapis will be entitled to one subscription right for each existing share held. The exercise of one subscription right will entitle the holder to subscribe for one new share at the proposed subscription price of EUR 0.46 per new share. In addition, those who will exercise their subscription rights will be entitled to subscribe for a number of additional new shares at the subscription price (oversubscription rights). The total gross proceeds will amount to approximately EUR 451.1 million.

The Company intends to use the net proceeds from the share capital increase to repay part of its existing short-term debt, finance expected working capital requirements and pursue targeted acquisitions of companies and other assets, in order to further support its growth strategy in the Greek and South-Eastern European healthcare markets.

Alapis has been informed that Lamda Partners L.P., a private equity fund, has irrevocably undertaken to participate in the share capital increase through one or more of its wholly owned subsidiaries by investing approximately EUR 90.2 million through the exercise of 196,120,044 rights, representing 20% of the new ordinary shares. Such rights will be acquired from Dr. Lavrentis Lavrentiadis or in the open market. The Company was also informed that Dr.Lavrentiadis is a director of the general partner of Lamda Partners L.P.

A syndicate of international firms composed of ABN AMRO, BofA Merrill Lynch, BNP PARIBAS, Deutsche Bank AG London Branch and Jefferies has agreed to subscribe or procure subscribers for any new shares which may remain unsubscribed at the end of the subscription period, subject to customary terms and conditions.

The Company's prospectus that will be prepared in relation to the share capital increase will be subject to approval by the Hellenic Capital Market Commission.

The Company will endeavour to complete the capital increase by the end of September, subject to obtaining all regulatory and other approvals in a Timely manner.

The decision of the Board of Directors is pursuant to the authority given to it by the second repeat Extraordinary General Meeting of Alapis' shareholders held on 29 September 2008.

    Further inquiry note:

    Norbert Schmidt-Gollas
    n.gollas@alapis.eu
   http://www.alapis.eu
    Alapis
    Aftokratoros Nikolaou str., No 2,
    p.c.176 71 Athens
    tel. +30-213-0175000-1
    fax +30-210-9238460

    emitter:         ALAPIS S.A.
                     Aftokratoros Nikalaou str. 2
                     17671 Athen
    phone:           +30-213-0175000-1
    FAX:             +30-210-923-8460
    mail:            info@alapis.eu
    WWW:            http://www.alapis.eu
    sector:          Pharmaceuticals
    ISIN:            GRS322003013



'/>"/>
SOURCE ALAPIS S.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology: